Biogen
BIIB • NASDAQ
Biogen is a drug manufacturers - general company in the healthcare sector trading on NASDAQ, led by CEO Christopher A. Viehbacher, with a market cap of $27.0B.
CEOChristopher A. Viehbacher
Next Earnings
Upcoming earnings announcement for Biogen
Date
Thursday, April 30, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$3.05
Revenue Estimate
$2.2B
Earnings History
Past 12 earnings reports for Biogen
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | Q4 2025 | $1.99Est: $1.62 | +22.8% | $2.3BEst: $2.2B | +3.3% |  10-K |
| Oct 30, 2025 | Q3 2025 | $4.81Est: $3.89 | +23.7% | $2.5BEst: $2.3B | +8.2% | 10-Q |
| Jul 31, 2025 | Q2 2025 | $5.47Est: $3.91 | +39.9% | $2.6BEst: $2.3B | +13.9% | 10-Q |
| May 1, 2025 | Q1 2025 | $3.02Est: $2.52 | +19.8% | $2.4BEst: $2.2B | +9.0% | 10-Q |
| Feb 12, 2025 | Q4 2024 | $3.44Est: $3.35 | +2.7% | $2.5BEst: $2.4B | +2.3% | 10-K |
| Oct 30, 2024 | Q3 2024 | $4.08Est: $3.79 | +7.7% | $2.5BEst: $2.4B | +1.5% | 10-Q |
| Aug 1, 2024 | Q2 2024 | $5.28Est: $4.02 | +31.3% | $2.5BEst: $2.4B | +3.6% | 10-Q |
| Apr 24, 2024 | Q1 2024 | $3.67Est: $3.44 | +6.7% | $2.3BEst: $2.3B | -0.8% | 10-Q |
| Feb 13, 2024 | Q4 2023 | $2.95Est: $3.18 | -7.2% | $2.4BEst: $2.5B | -3.2% | 10-K |
| Nov 8, 2023 | Q3 2023 | $4.36Est: $3.99 | +9.3% | $2.5BEst: $2.4B | +5.9% | 10-Q |
| Jul 25, 2023 | Q2 2023 | $4.02Est: $3.77 | +6.6% | $2.5BEst: $2.4B | +3.6% | — |
| Apr 25, 2023 | Q1 2023 | $3.40Est: $3.28 | +3.7% | $2.5BEst: $2.3B | +5.3% | — |